Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379771 | 1.00 | EPHX1 (0.50) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| SCHEMBL29291474 | 1.00 | EPHX1 (0.50) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| SCHEMBL1327157 | 1.00 | EPHX1 (0.50) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| SCHEMBL29291470 | 1.00 | EPHX1 (0.50) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| SCHEMBL8915603 | 0.97 | EPHX1 (0.48) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| Water SCHEMBL28513313 | 0.97 | EPHX1 (0.48) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| Hydrochloric Acid SCHEMBL6921995 | 0.97 | EPHX1 (0.48) | EPHX1ALOX5HPGDKMT2ASLC1A3 | |
| SCHEMBL302210 | 0.97 | — | — | |
| SCHEMBL303513 | 0.92 | — | — | |
| SCHEMBL6270171 | 0.88 | ANPEP (0.44) | EPHX1ALOX5HPGDKMT2ASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1577 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | claimed |
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | claimed |
| WO-2017024010-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | claimed |
| CN-102292323-B | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME | 2014-12-24 | — | — | CN | claimed |
| US-20140187532-A1 | 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-03 | — | — | US | claimed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | claimed |
| EP-2430019-B1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | claimed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-6376491-B1 | BENZOFURAN DERIVATIVES FOR TREATMENT OR PREVENTION OF MYCOSIS IN MAMMALS | BASILEA PHARMACEUTICA AG (CH) | 2002-04-23 | — | — | US | claimed |
| WO-2002024646-A1 | DELTA1-PYRROLINES USED AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2002-03-28 | — | — | WO | claimed |
| EP-1149094-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | Basilea Pharmaceutica AG (CH) | 2001-10-31 | — | — | EP | claimed |
| CN-1311796-A | Peptide antiangiogenic agents | ABBOTT LAB (US) | 2001-09-05 | — | — | CN | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-2000037464-A2 | 4-(AMINOALKOXY)BENZOFURANS AS N-MYRISTOYLTRANSFERASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2000-06-29 | — | — | WO | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| CN-86108626-A | Phenylformic acid and benzoate derivatives with anti-inflammatory and pain palliation efficacy | — | 1987-07-22 | — | — | CN | claimed |
| US-4000287-A | HYPOTENSIVES, ANTIARRHYTHMIC | CIBA-GEIGY CORPORATION (US) | 1976-12-28 | — | — | US | claimed |
| US-3935247-A | COBALT OR COPPER PHTHALOCYANINE CATALYST | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1976-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187532-A1 | 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | TYR, DDT, TH | EPHX1 216/4885ALOX5 898/4885HPGD 152/4885 |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | SLC2A2, SLC2A1, SLC5A2 | EPHX1 2528/4885ALOX5 901/4885HPGD 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.